Scientists at the University of Central Florida in Orlando have revived a dormant gene found in humans and coaxed it to produce retrocyclin, a protein that resists HIV.
Lead scientist Alexander Cole used aminoglycosides, drugs commonly used to fight bacterial infections, to trigger the production of the sleeping protein expressed by the retrocyclin gene."It could make a huge difference in the fight against HIV," Cole said. "Much more work would be needed to demonstrate the safety and effectiveness of this approach. We would certainly have to have human trials, but these findings represent a promising step in that direction."
HIV is the virus that causes AIDS. The disease, most often transmitted sexually, affects 4.3 million people worldwide, according to the World Health Organization. About 14,560 people die annually from HIV-related complications each year in the United States alone, according to the Centers for Disease Control.
Dozens of scientists around the world are looking for ways to prevent the transmission of the disease. Cole's journey into this area of research began while he was a postdoctoral fellow in the Department of Medicine at the University of California at Los Angeles. While there, he and his colleagues discovered that similar retrocyclin proteins found in early primates appeared to prevent HIV infections in cell cultures. The same gene exists in humans, but because of a mutation, it no longer produces the protein.
Now, in collaboration with researchers at UCLA, the Centers for Disease Control and his team at UCF, Cole has found that restoring the production of retrocyclins prevents HIV entry. He found a way to get the gene to produce the retrocyclins and then showed that the retrocyclins appear to prevent the transmission of HIV. He applied aminoglycoside antibiotics to vaginal tissues and cervical cells in his lab and found the antibiotic appears to stimulate those cells and tissues to produce retrocyclins on their own.
He said there is a good possibility the aminoglycoside antibiotics will be used in a cream or gel format that could someday be a simple way to prevent the transmission of HIV from men to women.
Cole arrived at UCF in 2003 and continues his work here with more than $4 million in grants from the National Institutes of Health.
Cole has degrees from the College of William and Mary and The University of Medicine and Dentistry of New Jersey. He completed a postdoctoral fellowship at UCLA, and he was an assistant professor in the Department of Medicine at UCLA before teaching at UCF.
He has published more than 50 peer-reviewed articles and has been a grant reviewer for several agencies, including the NIH, the Wellcome Trust and the National Science Foundation.
UCF Stands For Opportunity --The University of Central Florida is a metropolitan research university that ranks as the 5th largest in the nation with more than 50,000 students. UCF's first classes were offered in 1968. The university offers impressive academic and research environments that power the region's economic development. UCF's culture of opportunity is driven by our diversity, Orlando environment, history of entrepreneurship and our youth, relevance and energy.
Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel
The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
05.12.2016 | Power and Electrical Engineering
05.12.2016 | Information Technology
05.12.2016 | Earth Sciences